Allarity Therapeutics Q3 net loss widens on one-time expense
ALLR•Allarity Therapeutics reported a third-quarter net loss of $6.2 million, with a $3.2 million stenoparib API manufacturing charge the main driver. It expects Q4 earnings of $0.01 to $0.04 per share, but forecasts a 2026 full-year loss of $0.73 to $0.76 per share.
1. Quarterly results and outlook
Allarity Therapeutics reported a Q3 net loss of $6.2 million. A $3.2 million charge for stenoparib API manufacturing was the main driver of higher research and development expenses and the wider loss. The company expects Q4 earnings of $0.01 to $0.04 per share, driven by a one-time gain from debt extinguishment, and anticipates a 2026 full-year loss of $0.73 to $0.76 per share.
2. Business updates
The company signed its first revenue-generating contract for CLIA lab services and expanded its research capabilities.
